日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

有效载荷多样化克服耐药性并指导乳腺癌的序贯抗体药物偶联疗法。

Rampa Dileep Reddy, Seo Minji, Ogata Nanae, Yang Zhaoxuan, Sridhar Nithya, Fujii Takeo, Wannaphut Chalothorn, Maynard Jennifer A, Tsuchikama Kyoji, Sledge George W Jr, Ueno Naoto T, Lee Jangsoon

Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer

重新审视免疫检查点抑制剂时代三阴性乳腺癌的定义:HER2阴性浸润性乳腺癌激素受体百分比的最佳临界值

Fujii, Takeo; Iwase, Toshiaki; Shen, Yu; Fukui, Jami; Ueno, Naoto T

Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?

CDK4/6抑制剂治疗后氟维司群单药治疗的疗效:这是一种可行的选择吗?

Ogata, Nanae; Barnett, Brian G; Sharp, Nicholas J H; Fujii, Takeo; Iwase, Toshiaki; Dunn, Sandra E; Ueno, Naoto T

Revisiting surrogacy of pathological complete response for long-term survival in triple-negative breast cancer

重新审视病理完全缓解作为三阴性乳腺癌长期生存的替代指标

Yoshino, Toru; Zhang, Zao; Sato, Ryota; Lipkowitz, Stanley; Fujii, Takeo

Reassessing estrogen receptor expression thresholds for breast cancer prognosis in HER2-negative patients using shape restricted modeling

利用形状限制模型重新评估HER2阴性乳腺癌患者雌激素受体表达阈值对预后的影响

Dong, Wenli; Fujii, Takeo; Ning, Jing; Iwase, Toshiaki; Qin, Jing; Ueno, Naoto T; Shen, Yu

A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models.

CSF-1R 抑制剂在血液传播的临床前模型中既能预防又能治疗三阴性乳腺癌脑转移

Zhang Wei, Rahman Samiur, Wu Alex M L, Isanogle Kristine, Robinson Christina, Kumar Dinesh, Khan Imran, Wei Debbie, Zimmer Alexandra S, Fujii Takeo, Difilippantonio Simone, Lipkowitz Stanley, Steeg Patricia

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

一项针对伴或不伴有生殖系 BRCA 突变的转移性三阴性乳腺癌患者的 II 期试点研究,评估抗 PD-L1 药物 Durvalumab 和 PARP 抑制剂 Olaparib 的疗效。

Fujii Takeo, Cimino-Mathews Ashley, Lipkowitz Stanley, Lee Min-Jung, Nair Jayakumar, Solarz Britanny Brooke, Zimmer Alexandra, Redd Bernadette, Levy Elliot B, Rastogi Shraddha, Sato Nahoko, McCoy Ann, Steinberg Seth M, Lee Jung-Min

Healthcare provider perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions for breast cancer survivors

医疗保健提供者对用于支持乳腺癌幸存者个性化运动处方和讨论的临床决策工具的看法

Jayasekera, Jinani; Wilson, Oliver W A; Wojcik, Kaitlyn M; Kerr, Eleanor M; Brick, Rachelle; Berrigan, David; Sheng, Jennifer Yeong-Shin; Fujii, Takeo; Thomas, Kathleen; Parson, Henri K; Rajagopal, Padma Sheila; Street, Richard L Jr

Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"

新辅助恩扎卢胺和紫杉醇治疗管腔型雄激素受体富集型三阴性乳腺癌的 II 期研究:试验结果及对“ARness”的见解

Lim, Bora; Seth, Sahil; Yam, Clinton; Huo, Lei; Fujii, Takeo; Lee, Jangsoon; Bassett, Roland; Nasser, Sara; Ravenberg, Lisa; White, Jason; Clayborn, Alyson; Guerra, Gil; Litton, Jennifer K; Damodaran, Senthil; Layman, Rachel; Valero, Vicente; Tripathy, Debasish; Lewis, Michael; Dobrolecki, Lacey E; Lei, Jonathan; Candelaria, Rosalind; Arun, Banu; Rauch, Gaiane; Zhao, Li; Zhang, Jianhua; Ding, Qingqing; Symmans, W Fraser; Chang, Jeffrey T; Thompson, Alastair M; Moulder, Stacy L; Ueno, Naoto T

An Environment-Aware Adaptive Data-Gathering Method for Packet-Level Index Modulation in LPWA

一种面向低功耗广域网的包级索引调制环境感知自适应数据采集方法

Takyu, Osamu; Takeda, Keita; Miyamoto, Ryuji; Adachi, Koichi; Ohta, Mai; Fujii, Takeo